Evidence map›Paper›PMID 24126817›Full record

ReviewPediatric research2014

Stem cell-based therapy for neonatal lung disease: it is in the juice.

Moses E Fung, Bernard Thébaud

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pediatric research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Bronchopulmonary Dysplasia: Then, Now, and Next.Pediatric allergy, immunology, and pulmonology · 2020
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Bronchopulmonary dysplasia.Nature reviews. Disease primers · 2019
    Review
  16. Article
  17. [Mesenchymal stem cell transplantation in the treatment of bronchopulmonary dysplasia: opportunities and challenges].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2019
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Moses E FungWomen and Children's Health Research Institute, Cardiovascular Research Center and Pulmonary Research Group, University of Alberta, Edmonton, Alberta, Canada.
Bernard Thébaud1] Ottawa Hospital Research Institute, Regenerative Medicine Program, Sprott Centre for Stem Cell Research, Ottawa, Ontario, Canada [2] Department of Pediatrics, Children's Hospital of Eastern Ontario Research Institute, University of Ottawa, Ottawa, Ontario, Canada.

Funding

CIHR 84429-1
6 · The paper itself

Abstract

Bronchopulmonary dysplasia, the chronic lung disease of prematurity, is the most common complication in extremely premature infants (born before 28 wk gestation). Despite advances in perinatal care, modern clinical management remains devoid of therapies specifically promoting lung repair and lung growth. Recent progress in stem cell biology has uncovered the promise of stem/progenitor cells to repair damaged organs. Contrary to the original theory that stem cells engraft and repopulate the damaged organ, evidence suggests that stem cells act via a paracrine mechanism. This review highlights the preclinical evidence for the therapeutic potential of cell-based therapies in animal models of neonatal chronic lung injury and the multiple therapeutic avenues offered by soluble stem cell-derived factors.

Indexed as

Stem Cell TransplantationAnimalsBronchopulmonary DysplasiaClinical Trials as TopicDisease Models, AnimalHumansInfant, NewbornRats

Identifiers

PMID24126817
PMCPMC3940470

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.